2-(1,3-benzoxazol-2-ylthio)propanoic acid, also known as **Oxazepam**, is **not** a compound with that chemical structure. It's likely you are referring to **Oxazepam**, a benzodiazepine drug commonly used to treat anxiety and insomnia.
**Oxazepam** is a **benzodiazepine**, a class of drugs known for their calming and sedative effects. It works by enhancing the effects of a neurotransmitter called GABA (gamma-aminobutyric acid) in the brain. GABA is an inhibitory neurotransmitter, meaning it reduces the activity of neurons. By increasing GABA activity, oxazepam reduces anxiety and promotes relaxation.
**Here's why oxazepam is important for research:**
* **Mechanism of action:** Studying oxazepam helps researchers understand the mechanisms by which benzodiazepines work. This research can lead to the development of new drugs with similar effects but fewer side effects.
* **Therapeutic applications:** Oxazepam is an effective treatment for various anxiety disorders, including generalized anxiety disorder, social anxiety disorder, and panic disorder. It's also used to treat insomnia and pre-operative anxiety.
* **Pharmacokinetics and pharmacodynamics:** Researchers study the absorption, distribution, metabolism, and excretion (ADME) of oxazepam. This information helps to optimize drug dosage and timing for maximum therapeutic benefit.
* **Drug interactions:** Oxazepam can interact with other medications, including alcohol and certain antidepressants. Research helps to identify and understand these interactions to ensure safe and effective use.
* **Neurobiology of anxiety:** Oxazepam's effects on the brain provide insights into the neurobiology of anxiety and how different brain regions are involved. This knowledge is essential for developing new therapies for anxiety disorders.
In summary, oxazepam is an important compound for research due to its clinical significance, its role in understanding the mechanisms of benzodiazepine action, and its contributions to understanding the neurobiology of anxiety.
**Note:** It's crucial to consult with a healthcare professional for any medical information, including drug information.
| ID Source | ID |
|---|---|
| PubMed CID | 644583 |
| CHEMBL ID | 1540822 |
| CHEBI ID | 116168 |
| Synonym |
|---|
| smr000015282 |
| OPREA1_298441 |
| 2-(benzooxazol-2-ylsulfanyl)-propionic acid |
| MLS000068205 |
| CHEBI:116168 |
| AKOS000143011 |
| HMS1632C11 |
| 2-(1,3-benzoxazol-2-ylsulfanyl)propanoic acid |
| 252353-18-7 |
| CCG-144354 |
| HMS2395L13 |
| AKOS017268693 |
| CHEMBL1540822 |
| Q27198900 |
| 2-(1,3-benzoxazol-2-ylthio)propanoic acid |
| 2-(1,3-benzoxazol-2-ylsulfanyl)propanoic acid, aldrichcpr |
| SR-01000326708-1 |
| sr-01000326708 |
| 2-(benzo[d]oxazol-2-ylthio)propanoic acid |
| A924950 |
| CS-0333458 |
| 2-(benzo[d]oxazol-2-ylthio)propanoicacid |
| Class | Description |
|---|---|
| benzoxazole | Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 89.1251 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 15.1014 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 17.3608 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| P53 | Homo sapiens (human) | Potency | 70.7946 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 50.1187 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||